A Seattle-based biotechnology company is preparing to take a novel RNA platform out of the laboratory and into a clinical trial for brain cancer, extending a technology initially designed for infectious disease vaccines into the challenging field of oncology. HDT Bio, which operates in Seattle, has developed a self-amplifying RNA platform that differs in key respects from the messenger RNA technology used in the Covid-19 vaccines that reached broad public use in the early 2020s.
The company’s proprietary delivery system and the ability to program the RNA to encode tumor-specific targets represent the latest step in a research trajectory that began decades ago, when scientists first established that RNA could be delivered into cells inside lipid particles.
How Self-Amplifying RNA Works
Traditional mRNA vaccines deliver a single set of instructions to cells: produce a specific protein. Once the cell carries out that instruction, the RNA degrades.
HDT Bio’s platform uses self-amplifying RNA, or saRNA, which carries instructions both for the antigen — the substance the immune system is trained to recognize — and for the machinery to make additional copies of itself. The result is that the cell produces the target protein for a longer duration and at higher levels than standard mRNA can achieve. That persistence is especially important in cancer immunotherapy, where training the immune system to hunt down a tumor requires a sustained signal.
The saRNA can be programmed to encode tumor antigens or immune-stimulating molecules that direct the body’s defenses to attack cancer cells. The idea of using messenger RNA to prompt cells to make a target protein dates back decades, with early research dating to the late 20th century showing that RNA could be taken up by cells when packaged inside lipid nanoparticles.
Those early experiments laid the groundwork for the mRNA vaccines that later proved effective against the virus that causes Covid-19, demonstrating that temporary genetic instructions introduced into cells could train the immune system to recognize and respond to a threat. Self-amplifying RNA emerged as a later variation on that theme, carrying both the gene of interest and the replication machinery needed to boost production. The approach was initially explored for infectious disease applications before groups like HDT Bio began redirecting it toward cancer.
The shift is significant because brain tumors and other cancers have long resisted immune-based treatments that depend on a strong and lasting signal to generate an effective response.
Delivery System Designed for Stability
Delivery of the fragile RNA molecule presents a separate set of challenges, and HDT Bio has developed a system called LION, which stands for Lipid InOrganic Nanoparticle. This platform combines lipids with calcium phosphate, a mineral compound that helps protect the RNA from degradation and facilitates its entry into cells. Unlike some RNA formulations that require ultracold storage, the LION platform is designed to remain stable at refrigerator temperatures, a feature that could simplify distribution and make experimental therapies more accessible beyond large academic medical centers.
The company has published preclinical data demonstrating that this approach generates immune responses in animal models of cancer, providing the basis for the planned move into human testing. The clinical program will take place at McGill University in Montreal, where researchers intend to test the saRNA-LION combination in patients with brain cancer.
Although HDT Bio initially developed the technology for use in infectious disease vaccines, the same platform is being adapted for cancer immunotherapy. The ability to encode different tumor antigens or immune-stimulating molecules into the self-amplifying RNA gives the technology potential flexibility in targeting various cancer types, but the first human trial will focus on brain tumors, a class of malignancies that has historically been difficult to treat with conventional approaches.
Implications for Future Cancer Treatment
A platform that can be stored in a standard refrigerator and programmed to carry tumor targets could widen access to experimental immunotherapies beyond the large research centers where most such trials are currently conducted. The self-amplifying nature of the RNA means that each cell that takes up the payload becomes a miniature production facility, sustaining the immune-stimulating signal for longer than standard mRNA would allow.
This feature may be critical for overcoming the immunosuppressive environment typical of brain tumors, which often evade detection by the immune system. The upcoming trial at McGill will provide the first human data on whether the preclinical immune responses observed in animal models translate into clinical benefit for patients. HDT Bio, based in Seattle, continues to work on both infectious disease and cancer applications of its saRNA and LION technologies, building on decades of fundamental RNA research that reached a turning point with the successful deployment of mRNA vaccines in the early 2020s.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Self-amplifying RNA platform enters brain cancer clinical trial”, “description”: “SEATTLE, July 13 — A Seattle-based biotechnology company is preparing to take a novel RNA platform out of the laboratory and into a clinical trial…”, “datePublished”: “2026-07-13T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Ethan Smith”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
